Neolife funded this study to (apparently) support the release of a new product to market, “Neolife Botanical Balance”, a couple months after publication. N=30

Neolife funded this study to (apparently) support the release of a new product to market, “Neolife Botanical Balance”, a couple months after publication. N=30 short-term ensures minimum chance of detecting side effects to provide plausible deniability to the FDA. Age range 40-60 excludes the less wealthy <40 and those higher risk of death age ranges >60. Nutrition studies of the general population with N<1000, without any qualifying factor such as “extremely rare cancer subgroup”, ought to be banned at HN.